Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2011-07-19
2011-07-19
Duffy, Patricia A (Department: 1645)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C424S239100
Reexamination Certificate
active
07982006
ABSTRACT:
This invention pertains in part to the development of a vaccine for poultry against necrotic enteritis (NE). The vaccine utilizes a protective antigen that is a mutated, full-length, non-toxicClostridium perfringens(Cp) α-toxin protein (Mcpa). Utility of this vaccine was demonstrated by reduction of lesion severity in NE challenge trails, for example. Also disclosed herein are novel approaches for producing this vaccine in significant quantities. One exemplified approach involves producing NE vaccine (mutated alpha toxin) in bacterial expression systems, preferably utilizing thePseudomonas fluorescenssystem, for commercial use in controlling NE in the poultry industry. The subject vaccines can be administered preferably to chickens in several different ways. A novel, Type VI alpha toxin from chicken isolates of Cp is also disclosed.
REFERENCES:
patent: 6248329 (2001-06-01), Chandrashekar et al.
patent: WO 2006/113772 (2006-10-01), None
Sheedy et al (Journal of Clinical Microbiology, 42(3):1345-1347, 2004).
Herbert, et al., The Dictionary of Immunology, Academic Press, 1 page, 1995.
Ellis, R.W. (Chapter 29 of “Vaccines” Plotkin, S.A. et al. (eds) published by W.B. Saunders company (Philadelphia) in 1988, especially p. 571.
Sheedy, et al., Journal of Clinical Microbiology, 42(3): 1345-1347, 2004.
Data Base EMBL,Clostridium perfringensstrain NRRL B-23700 phospholipasae C (plc) gene, complete cds. Accession No. DQ184119, May 5, 2006.
Database UniProt, “Phospholipasae C.” Accession No. Q1HXE9, Jun. 13, 2006.
Guillouard, I., et al., Use of site-directed mutagenesis to probe structure-function relationships of alpha-toxin fromClostridium perfringens. Infection and Immunity, Jul. 1996, pp. 2440-2444, vol. 64, No. 7.
Nagahama, M. et al., “Site-directed mutagenesis of histidine residues inClostridium perfringensalpha-toxin” Journal of Bacteriology, Mar. 1995, pp. 1179-1185, vol. 177, No. 5.
Nagahama, M. et al., “Site-specific mutagenesis ofClostridium perfringensalpha-toxin: replacement of ASP-56, Asp-130, or G1u152 causes loss of enzymatic and hemolytic activities.” Infection and Immunity, Aug. 1997, pp. 3489-3492, vol. 65, No. 8.
Rooney, et al., “Analysis of core housekeeping and virulence genes reveals cryptic lineages ofLcostridium perfringensthat are associated with distinct disease presentations.” Genetics, Apr. 2006, pp. 2081-2092, vol. 172, No. 4.
Schoepe, H., e tal. “Immunization with an alphatoxin varians 121A/91-R212H protects mice againstClostridium perfringensalphatoxin” Anaerobe, Feb. 2006, pp. 44-48, vol. 12, No. 1.
Schoepe, et al., “Naturally occurringClostridium perfringensnontoxic alpha-toxin variant as a potential vaccine candidate against apha-toxin-associated disease”, Infection and Immunity, Nov. 2001, pp. 7194-7196, vol. 69, No. 11.
Williamson, E.D., et al., “A genetically engineered vaccine against the alpha-toxin ofClostridium perfringensprtects mice against experimental gas gangrene.”, Vaccine, Sep. 1993, pp. 1253-1258, vol. 11, No. 12.
Feng, et al., Infection and Immunity, 64(1):363-365, 1996.
Ainley William M.
Armstrong Janna
Madduri Krishna
Merlo Donald J.
Shen Liu Y.
Baker & Daniels LLP
Dow AgroSciences LLC
Duffy Patricia A
Maciak Ronald S.
LandOfFree
Clostridium perfringens alpha toxin proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Clostridium perfringens alpha toxin proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Clostridium perfringens alpha toxin proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2741625